CL2018003452A1 - Formulaciones nasales semi-sólidas y líquidas visuales de cannabinoides. - Google Patents

Formulaciones nasales semi-sólidas y líquidas visuales de cannabinoides.

Info

Publication number
CL2018003452A1
CL2018003452A1 CL2018003452A CL2018003452A CL2018003452A1 CL 2018003452 A1 CL2018003452 A1 CL 2018003452A1 CL 2018003452 A CL2018003452 A CL 2018003452A CL 2018003452 A CL2018003452 A CL 2018003452A CL 2018003452 A1 CL2018003452 A1 CL 2018003452A1
Authority
CL
Chile
Prior art keywords
compositions
semi
excipients
cannabinoids
methods
Prior art date
Application number
CL2018003452A
Other languages
English (en)
Inventor
Nathan Bryson
Avinash Chander Sharma
Original Assignee
Acerus Labs Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=60478110&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2018003452(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Acerus Labs Inc filed Critical Acerus Labs Inc
Publication of CL2018003452A1 publication Critical patent/CL2018003452A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/348—Cannabaceae
    • A61K36/3482—Cannabis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/577—Malvaceae (Mallow family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Medical Informatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pain & Pain Management (AREA)
  • Inorganic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

SE DESCRIBEN COMPOSICIONES FARMACÉUTICAS QUE CONTIENEN CANNABINOIDES ADECUADAS PARA ADMINISTRACIÓN NASAL. LAS COMPOSICIONES COMPRENDEN LOS CANNABINOIDES MENCIONADOS ANTERIORMENTE Y LOS EXCIPIENTES SELECCIONADOS DE MANERA QUE LAS COMPOSICIONES SON LÍQUIDOS SEMISÓLIDOS O VISCOSOS. EN REALIZACIONES PREFERIDAS, EL CANNABINOIDE ES A9-TETRAHIDROCANNABINOL (THC) O CANNABIDIOL (CBD). LOS EXCIPIENTES SON PREFERIBLEMENTE UNA MEZCLA DE UN VEHÍCULO ACEITOSO (TAL COMO ACEITE DE RICINO O ACETATO DE SACAROSA ISOBUTIRATO) Y UN AGENTE HUMECTANTE / TENSIOACTIVO (COMO OLEOYIL POLIOXILGLICÉRIDOS). LAS COMPOSICIONES PUEDEN COMPRENDER ADEMÁS ESPESANTES (TALES COMO DIÓXIDO DE SILICIO) Y OTROS EXCIPIENTES. SE DESCRIBEN MÉTODOS PARA FABRICAR Y ADMINISTRAR LAS COMPOSICIONES, ASÍ COMO MÉTODOS PARA USAR LAS COMPOSICIONES EN EL TRATAMIENTO DE TRASTORNOS COMÚNMENTE CONOCIDOS POR SER AFECTADOS POR LOS CANNABINOIDES.
CL2018003452A 2016-06-02 2018-12-03 Formulaciones nasales semi-sólidas y líquidas visuales de cannabinoides. CL2018003452A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662344486P 2016-06-02 2016-06-02
US201662426403P 2016-11-25 2016-11-25

Publications (1)

Publication Number Publication Date
CL2018003452A1 true CL2018003452A1 (es) 2019-06-21

Family

ID=60478110

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2018003452A CL2018003452A1 (es) 2016-06-02 2018-12-03 Formulaciones nasales semi-sólidas y líquidas visuales de cannabinoides.

Country Status (12)

Country Link
US (1) US20170348276A1 (es)
EP (1) EP3478270A4 (es)
KR (1) KR102433459B1 (es)
CN (1) CN109789090A (es)
BR (1) BR112018075073A2 (es)
CA (1) CA3026274A1 (es)
CL (1) CL2018003452A1 (es)
CO (1) CO2018013654A2 (es)
MX (1) MX392668B (es)
TW (1) TWI790204B (es)
UY (1) UY37271A (es)
WO (1) WO2017208072A2 (es)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9907823B1 (en) 2014-11-07 2018-03-06 Eric H. Kuhrts Water-soluble phytocannabinoid formulations
MX2020003606A (es) 2017-09-28 2020-10-28 Zynerba Pharmaceuticals Inc Tratamiento del sindrome del cromosoma x fragil con canabidiol.
US12582664B2 (en) 2017-09-28 2026-03-24 Harmony Biosciences Management, Inc. Treatment of fragile x syndrome with cannabidiol
US20190240148A1 (en) * 2018-02-07 2019-08-08 Tarukino Holdings, Inc. Lubricant composition and method for preparing the composition
WO2019172876A1 (en) * 2018-03-05 2019-09-12 Eric Kuhrts Water-soluble phytocannabinoid formulations
US11020357B2 (en) * 2018-03-19 2021-06-01 Alexandra Yerike Compound for use in relief of pain and method to produce thereof
EP3856172A4 (en) * 2018-09-28 2022-10-05 Visceral Therapeutics Inc. PHARMACEUTICALLY ACTIVE CANNABIS-BASED COMPOSITIONS AND METHODS FOR USE IN THE TREATMENT OF GASTROINTESTINAL CONDITIONS
US20200170962A1 (en) * 2018-11-30 2020-06-04 F. Markus Leweke Nasal cannabidiol compositions
WO2020118437A1 (en) * 2018-12-14 2020-06-18 Acerus Biopharma Inc. Active ester derivatives of testosterone, compositions and uses thereof
MX2021007076A (es) 2018-12-14 2021-08-11 Zynerba Pharmaceuticals Inc Tratamiento para el sindrome de supresion del 22q11.2 con cannabidiol.
BR102018076973A2 (pt) * 2018-12-21 2020-09-15 Entourage Participações S.A. Composição farmacêutica compreendendo extrato de cannabis, produto farmacêutico, processo de preparação da dita composição
WO2020142692A1 (en) * 2019-01-04 2020-07-09 Columbia Care Llc Topical formulations having cannabinoid
US20200215024A1 (en) * 2019-01-08 2020-07-09 Replennabis LLC Cannabinoid formulations for treating alcohol hangover
US20220110887A1 (en) * 2019-02-08 2022-04-14 Schedule 1 Therapeutics, Inc. Compositions comprising cannabinoids and methods of use thereof
US10993928B2 (en) * 2019-04-26 2021-05-04 Natural Extraction Systems, LLC Compositions comprising non-crystalline forms of cannabidiol
CA3139288A1 (en) * 2019-05-23 2020-11-26 Ramachandra MUKUNDA Compositions and methods using cannabinoids for treating stammering/stutering and symptoms of tourette syndrome
CN110433133A (zh) * 2019-08-19 2019-11-12 中国人民解放军军事科学院军事医学研究院 治疗创伤后应激障碍的大麻二酚鼻用制剂
PL3946262T3 (pl) 2019-08-30 2024-11-25 Evie Sa Wypełnione granulki, sposób ich wytwarzania i ich zastosowania
GB2588455B (en) * 2019-10-25 2022-12-21 Gw Res Ltd Cannabinoid compound
EP4069215A4 (en) * 2019-12-06 2024-01-17 Jlabs Beauty LLC TOPICAL COMPOSITIONS CONTAINING ROSE OIL AND CANNABIDIOL AND METHODS OF PREPARING AND USING THE SAME
TWI708835B (zh) * 2020-01-17 2020-11-01 和協工程股份有限公司 緩釋型釋碳凝膠基質及土壤整治方法
CH717205A1 (de) * 2020-03-11 2021-09-15 Jk Holding Gmbh Verwendung von Cannabinoiden in Therapie- und Wellnessgeräten.
US20210322343A1 (en) * 2020-04-15 2021-10-21 Farzana Shaheen Nasally administered pharmaceutical composition for the treatment of epilepsy and related disorders
WO2021231810A1 (en) * 2020-05-14 2021-11-18 Augusta University Research Institute, Inc. Cannabidiol as a therapeutic modality for covid-19
WO2021257913A1 (en) * 2020-06-20 2021-12-23 Chavan Neha Compositions for solubilizing water-insoluble active ingredients
EP3984522A1 (de) * 2020-10-19 2022-04-20 Shima Khaki Zusammensetzung, vorrichtung und verwendung
US12029720B2 (en) 2021-04-29 2024-07-09 Tilray Brands, Inc. Cannabidiol-dominant formulations, methods of manufacturing, and uses thereof
IT202100014909A1 (it) * 2021-06-08 2022-12-08 Velleja Res S R L Formulazioni oleose di cannabinoidi
CN113304109A (zh) * 2021-06-08 2021-08-27 内蒙古大唐药业股份有限公司 一种醋柳黄酮固体脂质纳米粒分散液及其制备方法
WO2023028708A1 (en) * 2021-09-02 2023-03-09 Canopy Growth Corporation Water-soluble cannabinoid compositions, methods of making and use
US11471905B1 (en) 2021-09-23 2022-10-18 Apackaging Group Llc All plastic airless pump dispenser
EP4186490A1 (en) * 2021-11-29 2023-05-31 Sanity Group GmbH Kit for preparing a medicament, cannabinoid composition, and preparation method
WO2023177675A1 (en) * 2022-03-15 2023-09-21 Milehigh Repro Solutions, Llc Methods and systems to reduce injury in treated tissues
JP2025512495A (ja) 2022-04-12 2025-04-17 シャッケルフォード・ファーマ・インコーポレーテッド 発作性障害の治療
WO2024010628A1 (en) * 2022-07-05 2024-01-11 Poviva Corp Pharmaceutical compositions and methods for treating hypertension
US11666543B1 (en) * 2022-07-05 2023-06-06 Poviva Corp. Pharmaceutical compositions and methods for treating hypertension
US11980593B2 (en) 2022-07-05 2024-05-14 Poviva Corp. Compositions and methods for treating hypertension
EP4518851A4 (en) * 2023-07-24 2025-07-30 Poviva Corp Compositions and methods for treating epilepsy
IT202300028233A1 (it) * 2023-12-28 2025-06-28 Linnea Sa Processo per la stabilizzazione di un oleolita
EP4642238A1 (en) * 2023-12-28 2025-11-05 Linnea S.A. Process for stabilising a macerated oil

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9726916D0 (en) * 1997-12-19 1998-02-18 Danbiosyst Uk Nasal formulation
AU2002231970B2 (en) * 2001-02-14 2007-08-16 CNX Therapeutics Limited Mucoadhesive pharmaceutical formulations
GB0103638D0 (en) * 2001-02-14 2001-03-28 Gw Pharmaceuticals Ltd Pharmaceutical formulations
GB2392093B (en) * 2002-08-14 2006-03-08 Gw Pharma Ltd Pharmaceutical formulations
AU2005314021B2 (en) * 2004-12-09 2010-02-11 Insys Therapeutics, Inc. Room-temperature stable dronabinol formulations
US20070060639A1 (en) * 2005-09-09 2007-03-15 University Of Kentucky Compositions and methods for intranasal delivery of tricyclic cannabinoids
MX395212B (es) * 2011-05-15 2025-03-21 Acerus Biopharma Inc Geles nasales de liberación controlada de testosterona, métodos y sistemas aplicadores multidosis pre cargados para administración pernasal.

Also Published As

Publication number Publication date
US20170348276A1 (en) 2017-12-07
BR112018075073A2 (pt) 2019-04-30
MX2018014978A (es) 2019-09-04
KR102433459B1 (ko) 2022-08-17
CA3026274A1 (en) 2017-12-07
EP3478270A2 (en) 2019-05-08
UY37271A (es) 2017-11-30
TW201801721A (zh) 2018-01-16
WO2017208072A3 (en) 2018-01-11
MX392668B (es) 2025-03-24
TWI790204B (zh) 2023-01-21
CN109789090A (zh) 2019-05-21
WO2017208072A2 (en) 2017-12-07
EP3478270A4 (en) 2019-11-27
KR20190034506A (ko) 2019-04-02
CO2018013654A2 (es) 2019-08-30

Similar Documents

Publication Publication Date Title
MX2018014978A (es) Composiciones nasales de cannabidiol.
MX2020012041A (es) Formulacion farmaceutica.
MX383529B (es) Formulación de goma de mascar que comprende partículas de un agente farmacéutico del grupo de cannabinoides, derivados de cannabinoides, terpenos o una mezcla de los mismos.
CO2022002685A2 (es) Nanopartículas lipídicas mejoradas para el suministro de ácidos nucleicos
FI2887923T3 (fi) Polyoksylilipidin tai polyoksylirasvahapon oftalminen formulaatio ja silmätilojen hoito
MX2020007784A (es) Uso de cannabinoides en el tratamiento de la epilepsia.
MX386182B (es) Preparaciones de agentes terapéuticos hidrófobos, métodos de elaboración y uso de los mismos.
MX2021009646A (es) Uso de cannabinoides en el tratamiento de epilepsia.
CO2019005729A2 (es) Preparación de complejos sólidos de ciclodextrina para suministro de ingredientes farmacéuticos activos oftálmicos
MX2020003415A (es) Compuestos de benzoxacepina oxazolidinona y métodos de uso.
MX2019001481A (es) Derivado de oxopicolinamida, metodo de preparacion y uso farmaceutico del mismo.
MX2018011278A (es) Composiciones para la liberacion controlada de cisteamina y el tratamiento sistemico de trastornos sensibles a la cisteamina.
PE20130216A1 (es) Formulacion topica para un inhibidor de jak
MX2019010757A (es) Métodos y composiciones relacionados con el tratamiento combinado con antiinflamatorios y nanoportadores sintéticos que comprenden un inmunosupresor.
PE20190318A1 (es) Composicion administrable oralmente
GT201300292A (es) Formulaciones peptídicas de liberación controlada.
MX391861B (es) Composiciones de canabinoide y usos
MX2016007067A (es) Microcapsulas lipidicas que comprenden de preferencia un retinoide y composicion que las contiene, su procedimiento de preparacion y su uso en dermatologia.
PE20151663A1 (es) Composiciones de principios activos farmaceuticos que contienen monoetil eter dietilenglicol u otros derivados de alquilo
CO7101246A2 (es) Compuesto de carbamato y preparación y uso de los mismos
EA201692334A1 (ru) Кортикостероидные композиции для местного применения
MX2015012559A (es) Novedosos fármacos de alta penetración y sus composiciones para el tratamiento de enfermedades de parkinson.
CL2021000938A1 (es) Composiciones estables de semaglutida y usos de las mismas
MX2024010721A (es) Formulaciones topicas que contienen ciclosporina y usos de las mismas.
PY1577621A (es) Composicion farmaceutica que comprende plasminogeno y uso para el mismo